Published in final edited form as:

Lancet Neurol. 2020 October ; 19(10): 840–848. doi:10.1016/S1474-4422(20)30273-8.

Identification of novel risk loci and causal insights for sporadic Creutzfeldt-Jakob disease: a genome-wide association study

A full list of authors and affiliations appears at the end of the article.

These authors contributed equally to this work.

Abstract

Background—Human prion diseases are rare and usually rapidly fatal neurodegenerative disorders, the most common being sporadic Creutzfeldt-Jakob disease (sCJD). Variants in the gene that encodes prion protein (PRNP) are strong risk factors for sCJD but, although the condition has heritability similar to other neurodegenerative disorders, no other genetic risk loci have yet been confirmed. We aimed to discover new genetic risk factors and the causal mechanisms.

Methods—Genome-wide association in European ancestry populations (patients diagnosed with probable or definite sCJD; identified at national CJD referral centres from 1990–2014; cases $n=5208$) using genotyping arrays and exome sequencing. Conditional, transcriptional and histological analyses of implicated genes/proteins in brain tissues and tests of the effects of risk variants on clinical phenotypes using deep longitudinal clinical cohort data.

Findings—We found 41 genome-wide significant single nucleotide polymorphisms and independently replicated findings at three loci associated with sCJD risk within PRNP (rs1799990; additive model $P=2.68 \times 10^{-15}$, OR=1.23; heterozygous model $P=1.01 \times 10^{-135}$), STX6 (rs3747957; $P=9.74 \times 10^{-9}$, OR=1.16) and GAL3ST1 (rs2267161; $P=8.60 \times 10^{-10}$, OR=1.18). Follow-up analyses suggest that associations at PRNP and GAL3ST1 are likely caused by common variants that alter the protein sequence, whereas risk variants in STX6 associate with increased expression of the major transcripts in disease-relevant brain regions. Alteration of STX6 expression does not modify prion propagation in a neuroblastoma cell model of mouse prion infection.

Interpretation—We present the first evidence of statistically robust associations in sporadic human prion disease that implicate intracellular trafficking and sphingolipid metabolism. Risk SNPs in STX6 are shared with progressive supranuclear palsy, a neurodegenerative disease associated with misfolding of protein tau, implicating shared mechanisms in prion-like disorders.

Funding—Medical Research Council (UK) and the National Institute of Health Research in part through the Biomedical Research Centre at University College London Hospitals NHS Foundation Trust. Many other national funders involved in international CJD surveillance and sample collection.

*Corresponding author: s.mead@prion.ucl.ac.uk +44 207 679 5142.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication.

Keywords

prion; GWAS; CJD; STX6; GAL3ST1

Introduction

Prion diseases are fatal neurodegenerative conditions of humans and animals caused by the propagation of prions, atypical infectious agents comprised solely or predominantly of host prion protein.¹ Prions are thought to propagate through a process of binding to normal prion protein, induction of conformational change by templating and fission of the polymeric assembly. Prion diseases can be acquired by exposure to prions in the diet, or through medical or surgical procedures, which may result in public health crises. The cattle prion disease, bovine spongiform encephalopathy (BSE), which transmitted to mostly young British and other European adults as variant Creutzfeldt-Jakob disease (vCJD),² led to enhanced clinical surveillance for all prion diseases worldwide. Inherited prion disease, caused only by mutations of the prion protein (*PRNP*) gene, causes approximately 10–15% of the annual incidence in most countries.³ The most common type of human prion disease is sporadic CJD (sCJD), a rapidly progressive dementia with a lifetime risk of approximately 1 in 5000, which occurs predominantly in older adults.^{4,5} Other than age and variation at *PRNP*, no risk factors for sCJD are known, leaving only speculative explanations for sporadic prion formation.

Polymorphisms of *PRNP* at codons 127, 129 and 219 alter the amino-acids and are strong genetic risk factors or modifiers of the disease phenotypes.³ Sibling or familial concurrence of sCJD has been reported, but not to the extent that chance concurrence can be eliminated as an explanation. There are no estimates of the heritability of sCJD based on family studies.⁶ Animal studies have identified risk factors for acquired prion diseases in and close to *Prnp*, and provided evidence for susceptibility loci on other chromosomes, yet elucidating the causal genes has proven challenging.³ Prions are thought to propagate through a process of binding to normal prion protein, induction of conformational change by templating and fission of the polymeric assembly. Many other neurodegenerative diseases are thought to share fundamental mechanisms with prion diseases including template-based protein misfolding and spreading of pathology associated with abnormally aggregated proteins in diseased brain tissue. If shared mechanisms exist this might implicate joint genetic risk factors.

This study follows on from previous genome-wide association studies (GWAS) in human prion diseases which have not been powerful enough to discover non-*PRNP* risk factors.^{7–10} Here we conducted a GWAS in sCJD, based on samples largely derived from clinical surveillance in countries with populations of predominantly European ancestries. We performed correlations with clinical phenotypes, and transcriptional, protein and cell model-based analyses with the aim of supporting specific causal genes at risk loci and allowing propositions of molecular mechanisms. We identified new risk factors for sCJD including variants which appear to have pleiotropic effects in neurodegenerative diseases.

Methods

Study design and participants

Samples from patients diagnosed with probable or definite sporadic CJD according to widely accepted criteria were provided by specialist or national surveillance centres in countries with populations of predominantly European ancestries (see appendix p 2 and Supplementary Methods appendix pp 28–32). Probable sporadic CJD criteria have varied over the course of sample collection for the study. Using modern diagnostic methods, including real-time quaking induced conversion assay with cerebrospinal fluid, a probable diagnosis refuted by post-mortem examination is extremely rare; but even >20 years ago probable sporadic CJD was highly accurate term. A total of 5208 cases were obtained from numerous countries/regions which were distributed across a two-stage study design: 4110 cases were genotyped using Illumina Omniexpress array in the discovery phase and an additional 1098 cases were genotyped at the lead variant in each hit locus using minor groove binding probes in the replication phase. Control data was obtained from publicly available datasets matched for country.

Procedures and statistical analysis

Genotypes were imputed using the Michigan Imputation Server and standard sample and genotyping quality control measures implemented to generate 6,314,492 high quality autosomal SNPs for subsequent analysis (see Supplementary Methods appendix pp 28–32). SNPTEST (v2.5.2) was used to perform the association test using an additive logistic regression model. Association statistics for the replication phase were generated using PLINK 1.9 in a fixed-effects meta-analysis of each cohort. The same model was used to study genetic association for kuru-resistance (older asymptomatic individuals exposed to kuru compared to young onset cases and those born after kuru exposure). Additional exome sequencing was performed on 501 CJD cases using the Illumina HiSeq2000 platform.

Further gene-based analysis was performed using MAGMA (v1.06) and VEGAS2 (v2.02) and SNP heritability estimates calculated using SumHer with standard specifications. CAVIAR and PAINTOR were utilised to generate a credible causal set for SNPs surrounding each significant locus based on linkage disequilibrium (LD) and functional annotations.^{11,12} eCAVIAR and eQTL colocalisation analysis was performed using 48 tissues included in the GTEx portal (v7).^{13,14}

Short-hairpin RNAs (shRNAs) targeting *Stx6* and *Prnp* were used to knockdown expression in N2aPK1/2 cells susceptible to infection with Chandler/RML prions. Prion propagation was measured using the Scrapie Cell Assay as previously described.¹⁵ Expression of each proposed gene was measured by RT-qPCR in cerebellum from 10 sCJD cases and 10 neurologically healthy controls. Immunohistology for syntaxin-6 and protein disulfide isomerase family A member 4 was performed on formalin-fixed paraffin-embedded frontal cortex and cerebellum of 19 sCJD cases and 15 non-neurological disease controls.

Data availability

Summary statistics are available through the GWAS catalog at NHGRI-EBI via study accession number GCST90001389. Further data available upon request.

Results

In the discovery phase we compared genome-wide genotype data from 4110 patients with probable or definite sCJD from countries of predominantly European ancestries with 13,569 control samples from countries matched for population (appendix pp 2–3). Imputation using the Michigan server resulted in 6,314,492 high quality autosomal SNPs after QC which were used for downstream association tests in SNPTEST with 10 population covariates. Genomic inflation (λ) was 1.026 (appendix p 16), indicating no significant and systemic bias related to population ancestry or platforms, so no further correction was done; the threshold for genome-wide significance was $P < 5 \times 10^{-8}$. Estimated SNP heritability (LDAC model: $h^2_{\text{SNP}} = 0.26$ (SD 0.014); GCTA model: $h^2_{\text{SNP}} = 0.24$ (SD 0.023)) was similar to common neurodegenerative diseases, in keeping with very rare reports of familial sCJD concurrence.^{6,16,17}

Further to the known association at *PRNP* on chromosome 20p13, two loci achieved genome-wide significance mapping to 1q25.3 (*STX6*) and 22q12.2 (*GAL3ST1*) (Figure 1; Table 1; appendix pp 17–19). Gene based testing with VEGAS2 additionally identified *PDIA4* ($P = 0.040$) and *BMERB1* ($P = 0.0014$) although testing with MAGMA did not support these associations (appendix pp 20–21). No significant gene-sets were found. A SNP in intron 1 of the *BMERB1* gene achieved borderline significance (rs6498552, $P = 5.75 \times 10^{-8}$, appendix p 21). Whilst we acknowledge that data from multiple SNPs at a locus are needed to directly replicate gene-based test results, we selected a lead SNP from the three genome-wide significant loci as well as from *PDIA4* and *BMERB1* for the replication phase.

In the replication phase we generated genotype data using minor groove binding probes from 1098 patients with probable or definite CJD, again from multiple countries of predominantly European ancestries, and compared with genotypes from 498,016 control samples from the same countries (appendix pp 2–3). Association testing provided replication evidence for *PRNP* (rs1799990, heterozygous genotype and to a lesser extent the minor allele is protective), *STX6* (rs3747957, minor allele conferred risk) and *GAL3ST1* (rs2267161, minor allele was protective) (Table 1). Next, we explored if those loci would also show an association in related prion diseases. Genotype data was generated for vCJD [acquired from exposure to BSE], iatrogenic CJD [caused by exposure to cadaveric pituitary-derived human growth hormone]; or kuru (and resistance to kuru) [a former epidemic of orally transmitted prion disease among people who lived in the Eastern Highlands Province of Papua New Guinea]. We found no evidence for association of rs3747957 in *STX6*, or rs2267161 in *GAL3ST1* with these phenotypes ($P > 0.05$), implying that these loci may confer risk specific to the sporadic form of human prion disease, although all tests were underpowered due to small sample size.^{7,9}

Sporadic CJD is known to comprise a range of different clinical and pathological phenotypes, broadly correlating with prion molecular strain types, the latter including

categorisation by different proportions of three glycoforms and the apparent molecular weight of abnormal PrP by western blotting.¹⁸ The National Prion Clinic London has conducted longitudinal observational cohort studies of CJD involving systematic clinical assessments of patients resulting in deep phenotype data.^{19,20} We tested rs1799990, rs3747957 and rs2267161 for association with age at clinical onset, clinical duration, the slope of decline in a functional measure of disease severity, along with 27 other phenotypic variables (appendix p 4). As expected rs1799990 in *PRNP* showed associations with several clinical and biomarker traits (10/30 tested hypotheses). We found no evidence for epistasis between discovered loci and genotypes at rs1799990, which is known to be a major determinant of clinical phenotype.

Because association in a genomic region might not be mediated through the nearest gene, we investigated the potential mechanisms underlying associations with *PRNP*, *STX6* and *GAL3ST1*. First we used CAVIAR to fine map the association signal at a locus through joint modelling of association statistics for all variants at a locus and estimation of a conditional posterior probability of causality whilst allowing for multiple plausibly functional SNPs.¹² Around *PRNP* most of the SNPs identified tagged rs1799990. Unexpectedly, a cluster of SNPs located 5' to those tagging rs1799990 (lead SNP rs12624635, not an eQTL) with low levels of LD to rs1799990 were also putatively causal, suggesting a potential additional signal at this locus (Figure 2a). Previous studies have reported that variants at the *PRNP* locus may confer an increased risk for sCJD, independently of rs1799990.^{21–24} To further delineate the genetic architecture of the *PRNP* risk locus we first performed an association analysis under a heterozygous model, which is more appropriate for the known mechanism and confirmed rs1799990 as the lead SNP, $P=1.01 \times 10^{-135}$ (appendix p 22). Next in a conditional analysis, adjusting for heterozygosity at rs1799990, the lead SNP was rs6139515 ($P=8.98 \times 10^{-4}$). This SNP, which is in low LD with rs1799990 ($r^2=0.04$), is correlated with *PRNP* transcript levels in tibial nerve in the GTEx eQTL database²⁵; $P=1.8 \times 10^{-6}$ (appendix p 23; appendix p 5). The conditional analysis provided no substantive evidence of an independent association signal at the CAVIAR lead SNP, rs12624635, $P=0.03$ (appendix p 23; appendix p 5).

The region of high LD surrounding rs3747957 in *STX6* resulted in a large causal set, making identification of a single causal variant more complex (Figure 2b). Subsequently, using eCAVIAR¹³, GTEx²⁵ and other eQTL databases, we identified a strong correlation between sCJD risk and increased expression of *STX6* mRNA in multiple brain regions, particularly in the caudate and putamen nuclei of the brain (putamen: rs3747957, $P=2.3 \times 10^{-13}$, GTEx; Figure 3). Both are key regions implicated in sCJD and are the most frequently abnormal brain regions at diagnostic brain magnetic resonance imaging.²⁶ Correlations between lead SNPs in *STX6*, rs11586493 and rs3747957, and other genes at the locus or within other tissues were absent or less strong (Figure 3, appendix p 12). These results suggest that elevated expression of *STX6* in brain regions confers an increased risk of sCJD. Using PAINTOR, a tool that integrates functional genomic annotation with association statistics, we next identified three SNPs (rs12754041, rs10797664 and rs6425657, each in strong LD with lead SNP rs3747957) with high posterior probability of being causal in four annotation groups (RoadMap_Assayed_NarrowPeak; Maurano_Science2012_DHS; RoadMap_Enhancers; Roadmap_ChromeHMM_15state).¹¹

As the GWAS signal is associated with only two SNPs at *GAL3ST1* (in strong LD with each other but low LD with all surrounding variants) these SNPs predominantly define the causal set, yet they are statistically indistinguishable from each other (Figure 2c). Using GTEx, neither SNP correlated with expression of genes at the locus in brain tissues. One of the SNPs, rs2267161, is a non-synonymous variant of *GAL3ST1* p.V29M. Close to p.V29M resides p.V34M (rs55674628, allele frequency=0.02; LD with rs2267161, $r^2=0.01$, $D'=1.00$, discovery $P=0.18$), the only common non-synonymous variants in European ancestries populations. These polymorphisms form three common haplotypes, rs2267161-C/rs55674628-C (CC), CT and TC with frequencies in the combined case-control dataset of 0.667, 0.018 and 0.315, respectively. We found no evidence of an association driven by the rs55674628-T allele using a haplotype-based test (appendix p 13). Furthermore, analyses of 501 CJD cases by exome sequencing²⁷ did not identify additional rare variants in *GAL3ST1* or *STX6*.

Expression of *STX6*, *GAL3ST1*, *PDIA4* and *BMERB1* mRNA was slightly reduced in bulk analysis of post-mortem cerebellar brain tissue from sCJD cases but only to a similar extent as genes suggested to be good comparators (appendix p 24).²⁸ Immunohistology of frontal cortex (19 sCJD; 15 controls) showed that syntaxin-6 expression is restricted to neurons of different sizes, whilst other cell types, probably astrocytes or oligodendrocytes, were less consistently stained. In the cerebellum, syntaxin-6 staining is observed in Purkinje cells and in large neurons of the dentate nucleus, whilst a fine granular staining is seen in the molecular layer (appendix p 25). In all neuron populations of cerebellum and forebrain, the staining pattern is fine granular, and is located in the cytoplasm, but does not extend into the processes. The staining pattern is compatible with the predicted target, the Golgi apparatus. The pattern for both syntaxin-6 and *PDIA4* was indistinguishable between CJD cases and controls (appendix p 26).

Based on GTEx data, we hypothesized that increased expression of *Stx6* in deep brain nuclei increases risk of prion disease. To test whether this might be conferred through facilitating prion propagation in mammalian neuronal cells, we depleted prion-susceptible mouse neuroblastoma-derived cells (N2aPK1/2)²⁹ of *Stx6* expression using RNA interference. Using the Automated Scrapie Cell Assay we measured the impact of *Stx6* knockdown on prion propagation^{15,29} using *Prnp* knockdown cells, known to inhibit prion propagation in this assay, as positive control.³⁰ Figure 4 shows that *Stx6* depletion, unlike *Prnp*, does not consistently reduces the ability of N2aPK1/2 cells to propagate RML prions.

Discussion

We report the first GWAS in a human prion disease powered to detect alleles with the modest effects typical of complex diseases. Further to the known effects at *PRNP* codon 129, we report two independently replicated loci, and evidence to support the conclusion that risk variants modify the primary sequence of the encoded protein (*GAL3ST1*) or increase expression in brain tissues (*STX6*). Whilst a multitude of potential binding partners for PrP and mechanisms for the modification of prion infection have been proposed, GWAS discoveries have special value because risk variants are implicitly causal in the human disease.³¹ Therapeutic targets underpinned by genetic evidence have better chances of

successful drug development, further encouraging research into the mechanisms that underpin these signals.³¹

Risk variants in sCJD might act at different disease stages: increasing the chance of the spontaneous generation of prions, reducing their clearance, enabling prion propagation throughout brain tissue, or modifying the downstream toxic effects of prion propagation on brain cells. We did not find any evidence of a role for risk variants in the modification of clinical or pathological disease phenotypes, or in modified expression of risk genes at the end stage of the disease, yet it is too early to draw confident conclusions in this respect. Altering the expression of *STX6* in a cellular model of prion infection did not modify the susceptibility of mouse cells to infection or the accumulation of abnormal forms of PrP. Our functional data therefore point to a role early in the disease process, perhaps by altering the risk of spontaneous prion formation in the brain, but studies in other models are warranted.

STX6 encodes syntaxin-6, an 11 exon, 255 amino-acid protein that localises to the trans-Golgi network, recycling and early endosomes. Syntaxin-6 is thought to form part of the t-SNARE complex involved in the decision of a target membrane to accept the fusion of a vesicle.³² The intracellular location of abnormal PrP in prion-infected cells involves the plasma membrane where conversion is primarily thought to occur,³⁰ as well as early and recycling endosomes, late endosomes, and the perinuclear region.³³ Other studies implicate the endocytic-recycling compartments (ERCs) and/or multivesicular bodies (MVBs) for the sites of generation of prions, and dysregulation of trafficking genes by sCJD.^{34,35} Intracellular trafficking has also been implicated in the degradation of prions.³⁶ The modification of trafficking of normal and/or abnormal PrP by syntaxin-6 might be a focus for future investigation (see our review for detailed discussion³⁷).

There has been considerable recent discussion about the extent to which neurodegenerative diseases associated with the accumulation of misfolded proteins or peptides are “prion-like” in their pathogenesis.³⁸ This concept provokes the suggestion that prion and prion-like disorders might share genetic risk factors. Progressive supranuclear palsy (PSP) is an uncommon neurodegenerative movement disorder associated with the accumulation of abnormal forms of microtubule-associated protein tau with four repeats.^{39,40} Variants in *STX6* are in a haplotype with SNPs previously identified as associated with PSP with shared risk alleles (appendix p 14).^{40,41} Pleiotropic effects at this locus between prion diseases and a tauopathy lend support to the concept of prion-like disorders and raise the prospect for genetically inspired interventions across multiple neurodegenerative disorders.

GAL3ST1 encodes galactose-3-O-sulfotransferase 1, a 423 amino acid protein that localises to the Golgi network in oligodendrocytes, the sole enzyme responsible for the sulfation of membrane sphingolipids to form sulfatides, a major brain lipid and component of the myelin sheath.⁴² Degradation of sulfatides is catalysed by *ARSA* in the lysosome; recessive defects in this enzyme cause metachromatic leukodystrophy, a lysosomal storage disorder associated with profound central and peripheral demyelination.⁴³ Knockout of *GAL3ST1* in mice results in a neurological phenotype associated with abnormal myelin maintenance with age, histological abnormalities at the paranodal junctions, and abnormal diffusion tensor imaging (DTI).⁴⁴ Furthermore, in a GWAS of UK Biobank participants, rs2267161 in *GAL3ST1* was

significantly associated with multiple changes in white matter microstructure measured using brain DTI.⁴⁵ Sphingolipid metabolism and myelin maintenance have both been previously implicated in PrP and prion diseases.^{46,47} Multiple genes in the sphingolipid metabolic pathways are dysregulated early in the pathogenesis of mouse prion diseases, a finding consistent between inbred mouse lines and prion strains.⁴⁸ Knockout of PrP in mouse, or naturally in goats, results in a demyelinating neuropathy, which in goats is associated with abnormal sphingolipid metabolism (see review for further discussion³⁷).
49–51

PDIA4 and *BMERB1* loci identified in the discovery phase by gene-wide analysis, were not replicated by single SNP tests, however the replication sample was necessarily limited by the rarity of the disease and the lead SNPs had a lower allele frequency than at other risk loci. Further attempts are justified as gene-based test results are driven by multiple SNPs at each locus.

In summary, we present the first evidence of statistically robust associations in sporadic human prion disease that implicate intracellular trafficking and sphingolipid metabolism. Future work might further test hypotheses derived from these discoveries in prion disease model systems, and examine the effects of genome-wide genetic variation on clinical, pathological and molecular phenotypes in sporadic and inherited prion diseases.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Authors

Emma Jones, BSc^{#1}, Holger Hummerich, PhD^{#1}, Emmanuelle Viré, PhD^{#1}, James Uphill, BSc¹, Athanasios Dimitriadis, BSc¹, Helen Speedy, PhD¹, Tracy Campbell, BSc¹, Penny Norsworthy, BSc¹, Liam Quinn, PhD¹, Jerome Whitfield, PhD¹, Jacqueline Linehan, BSc¹, Zane Jaunmuktane, FRCPath², Prof. Sebastian Brandner, MD³, Prof. Parmjit Jat, PhD¹, Akin Nihat, MBBS¹, Tze How Mok, MB¹, Parvin Ahmed, MSc¹, Prof. Steven Collins, MD⁴, Christiane Stehmann, PhD⁴, Shannon Sarros, BSc⁴, Gabor G Kovacs, PhD⁵, Michael Geschwind, PhD⁶, Aili Golubjatnikov, MS⁶, Karl Fronztek, PhD⁷, Prof. Herbert Budka, MD⁷, Prof. Adriano Aguzzi, PhD⁷, Hata Karamuji - o mi , MD⁸, Sven J van der Lee, PhD⁸, Carla A Ibrahim-Verbaas, PhD⁸, Prof. Cornelia M Van Duijn, PhD^{8,9}, Prof. Beata Sikorska, PhD¹⁰, Ewa Golanska, PhD¹⁰, Prof. Pawel Liberski, PhD¹⁰, Miguel Calero, PhD¹¹, Olga Calero, PhD¹¹, Pascual Sanchez Juan, PhD¹², Prof. Antonio Salas, PhD¹³, Federico Martín-Torres, PhD¹⁴, Elodie Bouaziz-Amar, PhD¹⁵, Stephane Haik, PhD^{16,17}, Prof. Jean-Louis Laplanche, PhD¹⁷, Jean-Phillipe Brandel, MD^{16,17}, Prof. Phillipe Amouyel, PhD¹⁸, Jean-Charles Lambert, PhD¹⁸, Prof. Piero Parchi, PhD^{19,21}, Anna Bartoletti-Stella, PhD²⁰, Sabina Capellari, MD^{20,21}, Anna Pileggi, PhD²², Anna Ladogana, MD²², Prof. Maurizio Pocchiari, MD²², Serena Aneli, PhD²³, Prof. Giuseppe Matullo, PhD²³, Prof. Richard Knight, FRCP(E)²⁴, Saima Zafar, PhD^{25,26}, Prof. Inga Zerr, MD²⁵, Stephanie Booth, DPhil²⁷, Michael B

Coulthart, PhD²⁸, Gerard H Jansen, MD²⁹, Katie Glisic, MA³⁰, Janis Blevins³⁰, Prof. Pierluigi Gambetti, MD³⁰, Prof. Jiri Safar, MD³⁰, Brian Appleby, MD³⁰, Prof. John Collinge, FRS¹, Prof. Simon Mead, PhD^{1,*}

Affiliations

¹MRC Prion Unit at UCL, Institute of Prion Diseases, 33 Cleveland St, London, W1W 7FF; National Prion Clinic, University College London Hospitals NHS Foundation Trust, London. ²Division of Neuropathology, University College London Hospitals NHS Foundation Trust, and Department of Clinical and Movement Neurosciences and Queen Square Brain Bank for Neurological Disorders, UCL Queen Square Institute of Neurology, London, UK. ³Division of Neuropathology, University College London Hospitals NHS Foundation Trust, and Department of Neurodegenerative disease, UCL Queen Square Institute of Neurology, Queen Square, London WC1N 3BG ⁴Australian National Creutzfeldt-Jakob Disease Registry, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, 3010, Australia. ⁵Institute of Neurology, Medical University of Vienna, Vienna, Austria; Current address: Department of Laboratory Medicine and Pathobiology and Tanz Centre for Research in Neurodegenerative Disease, University of Toronto, and Laboratory Medicine Program & Krembil Brain Institute, University Health Network, Toronto, Ontario Canada. ⁶UCSF Memory and Aging Center, Department of Neurology, University of California, San Francisco. ⁷Institute of Neuropathology, University of Zurich, Zurich, Switzerland. HB's current address: Medical University Vienna, Vienna, Austria. ⁸Department of Epidemiology, Erasmus Medical Centre, Rotterdam, the Netherlands ⁹Nuffield Department of Population Health, University of Oxford, UK. ¹⁰Department of Molecular Pathology and Neuropathology, Medical University of Lodz, Lodz, Poland. ¹¹Chronic Disease Programme (UFIEC-CROSADIS) and Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Instituto de Salud Carlos III, Madrid, Spain and Alzheimer Disease Research Unit, CIEN Foundation, Queen Sofia Foundation Alzheimer Center, Chronic Disease Programme Carlos III Institute of Health and Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain. ¹²Neurology Service, University Hospital Marqués de Valdecilla (University of Cantabria, CIBERNED and IDIVAL), Santander, Spain. ¹³Unidade de Xenética, Instituto de Ciencias Forenses (INCIFOR), Faculdade de Medicina, Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de Investigaciones Sanitarias (IDIS), Hospital Clínico Universitario de Santiago (SERGAS), Galicia, Spain ¹⁴Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clínico Universitario de Santiago de Compostela, Galicia, Spain ¹⁵Department of Biochemistry and Molecular Biology, Lariboisière Hospital, AP-HP, University of Paris, France ¹⁶Sorbonne Université, INSERM, CNRS UMR 7225, Institut du Cerveau et de la Moelle épinière, ICM, Paris, France ¹⁷Cellule nationale de référence des maladies de Creutzfeldt-Jakob, APHP, University Hospital Pitié-Salpêtrière, Paris, France ¹⁸Univ. Lille, Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE, Labex DISTALZ, Lille, France. ¹⁹IRCCS, Istituto delle Scienze

Neurologiche di Bologna, Bologna, Italy. ²⁰Department of Biomedical and Neuromotor Sciences, University of Bologna, Bologna, Italy ²¹Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy ²²Department of Neuroscience, Istituto Superiore di Sanità, Rome, Italy. ²³Department of Medical Sciences, Università degli studi di Torino, Via Verdi, Torino, Italy ²⁴National CJD Research and Surveillance Unit, Edinburgh, UK. ²⁵Department of Neurology, Clinical Dementia Center and National Reference Center for CJD Surveillance, University Medical School; German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany. ²⁶Biomedical Engineering and Sciences Department, School of Mechanical and Manufacturing Engineering (SMME), National University of Sciences and Technology (NUST), Islamabad, Pakistan. ²⁷Prion Disease Program, Public Health Agency of Canada, Winnipeg, Canada ²⁸Canadian Creutzfeldt-Jakob Disease Surveillance System, Public Health Agency of Canada, Ottawa, Canada. ²⁹Department of Pathology and Laboratory Medicine, University of Ottawa, Ottawa, Canada. ³⁰Departments of Pathology and Neurology, Case Western Reserve University, Cleveland, OH, USA; National Prion Disease Pathology Surveillance Center, Case Western Reserve University, Cleveland, OH, USA

Acknowledgements

We thank Richard Newton for support with images and UCL Genomics who did the array processing for cases. This study makes use of data generated by the Wellcome Trust Case-Control Consortium. A full list of the investigators who contributed to the generation of the data is available from www.wtccc.org.uk. Funding for the project was provided by the Wellcome Trust and Medical Research Council. We would like to thank patients, their families and carers, UK neurologists and other referring physicians, co-workers at the National Prion Clinic, our colleagues at the National Creutzfeldt-Jakob Disease Research and Surveillance Unit, Edinburgh. We thank past and present Directors of the Papua New Guinea Institute of Medical Research, the staff of the PNGIMR, especially the kuru project field team, and the communities of the kuru-affected region for their generous support. We gratefully acknowledge the help of the late Carleton Gajdusek, the late Joseph Gibbs and their associates from the former Laboratory of Central Nervous System Studies of the National Institutes of Health, Bethesda, USA for archiving and sharing old kuru samples. The kuru studies were initially funded by a Wellcome Trust Principal Research Fellowship in the Clinical Sciences to JC, and since 2001, and all other aspects of the work by the Medical Research Council. Several authors at UCL/UCLH receive funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. Some of this work was supported by the Department of Health funded National Prion Monitoring Cohort study. SJC receives an NHMRC Practitioner Fellowship (ID# APP1105784). Tze How Mok is supported by a Fellowship award from Alzheimer's Society, UK (grant number 341 (AS-CTF-16b-007)) and CJD Support Network UK Research Support Grants. Funding for the collection of Polish samples for study was partially provided by the EU joint programme JPND and Medical University of Lodz. We thank Dr. Maria Styczynska from Mossakowski Medical Research Centre; Polish Academy of Sciences; Warsaw, for kindly providing control DNA samples for the Polish cohort. The Italian national surveillance of Creutzfeldt-Jakob disease and related disorders is partially supported by the Ministero della Salute, Italy. The German National Reference Centre for TSE is funded by grants from the Robert-Koch-Institute. The Dutch National Prion Disease Registry is funded by the National Institute for Public Health and the Environment (RIVM), which is part from the Ministry for Health, Welfare and Sports, The Netherlands. PS-J was supported by Instituto de Salud Carlos III [Fondo de Investigación Sanitaria, PI16/01652] Accion Estrategica en Salud integrated in the Spanish National I+D+i Plan and financed by Instituto de Salud Carlos III (ISCIII) - Subdirección General de Evaluación and the Fondo Europeo de Desarrollo Regional (FEDER - "Una Manera de Hacer Europa"). We thank Inés Santiuste and the Valdecilla Biobank (PT17/0015/0019), integrated in the Spanish Biobank Network, for their support and collaboration in sample collection and management. The study on Italian controls was supported by the Ministero dell'Istruzione, dell'Università e della Ricerca - MIUR project "Dipartimenti di Eccellenza 2018 - 2022" (n° D15D18000410001) to the Department of Medical Sciences, University of Torino (G.M.) and the AIRC - Associazione Italiana per la Ricerca sul Cancro (IG 2018 Id.21390 to G.M.). The Three-City Study was performed as part of a collaboration between the Institut National de la Santé et de la Recherche Médicale (Inserm), the Victor Segalen Bordeaux II University and Sanofi-Synthelabo. The Fondation pour la Recherche Médicale funded the

preparation and initiation of the study. The 3C Study was also funded by the Caisse Nationale Maladie des Travailleurs Salariés, Direction Générale de la Santé, MGEN, Institut de la Longévité, Agence Française de Sécurité Sanitaire des Produits de Santé, the Aquitaine and Bourgogne Regional Councils, Agence Nationale de la Recherche, ANR supported the COGINUT and COVADIS projects. Fondation de France and the joint French Ministry of Research/INSERM «Cohortes et collections de données biologiques» programme. Lille Génopôle received an unconditional grant from Eisai. The Three-city biological bank was developed and maintained by the laboratory for genomic analysis LAG-BRC - Institut Pasteur de Lille. This work was also funded by the Pasteur Institut de Lille, the Lille Métropole Communauté Urbaine, the Haut-de France council, the European Community (FEDER) and the French government's LABEX DISTALZ program (development of innovative strategies for a transdisciplinary approach to Alzheimer's disease). The French National Surveillance Network for Creutzfeldt-Jakob disease is supported by Santé Publique France.

Conflicts of Interest

Dr. Budka reports grants from Federal Office for Health, Swiss Government, during the conduct of the study. Dr. HAIK reports grants from Santé Publique France, during the conduct of the study; grants from LFB Biomedicaments, grants from Institut de Recherche Servier, grants from MedDay Pharmaceuticals, outside the submitted work; In addition, Dr. HAIK has a patent Method for treating prion diseases (PCT/EP2019/070457) pending. Dr. AMOUYEL reports personal fees from Fondation Alzheimer, personal fees and other from Genoscreen, outside the submitted work. Dr. Appleby reports grants from Centers for Disease Control and Prevention, during the conduct of the study. Fronztek reports grants from Ono Pharmaceuticals outside the submitted work. Dr. Mead reports grants from Medical Research Council (UK) and grants from National Institute of Health Research's Biomedical Research Centre at University College London Hospitals NHS Foundation Trust during the conduct of the study. Dr. Kovacs reports personal fees from Biogen, outside the submitted work. Dr. Collinge reports grants from Medical Research Council, grants from NIHR UCLH Biomedical Research Centre, during the conduct of the study; and I am a Director and shareholder of D-Gen Limited, an academic spinout in the field of prion disease diagnostics, decontamination and therapeutics. Dr. Pocchiari reports personal fees from Ferring Pharmaceuticals, personal fees from CNCCS (Collection of National Chemical Compounds and Screening Center), non-financial support from Fondazione Cellule Staminali, outside the submitted work. Dr. Geschwind has consulted for 3D Communications, Adept Field Consulting, Advanced Medical Inc., Best Doctors Inc., Second Opinion Inc., Gerson Lehrman Group Inc., Guidepoint Global LLC, InThought Consulting Inc., Market Plus, Trinity Partners LLC, Biohaven Pharmaceuticals, Quest Diagnostics and various medical-legal consulting. He has received speaking honoraria for various medical center lectures and from Oakstone publishing. He has received past research support from Alliance Biosecure, CurePSP, the Tau Consortium, and Quest Diagnostics. Dr. Geschwind serves on the board of directors for San Francisco Bay Area Physicians for Social Responsibility and on the editorial board of *Dementia & Neuropsychologia*.

References

1. Collinge J Prion diseases of humans and animals: Their causes and molecular basis. *Annu Rev Neurosci* 2001; 24: 519–50. [PubMed: 11283320]
2. Collinge J Variant Creutzfeldt-Jakob disease. *Lancet* 1999; 354(9175): 317–23. [PubMed: 10440324]
3. Mead S, Lloyd S, Collinge J. Genetic Factors in Mammalian Prion Diseases. *Annu Rev Genet* 2019; 53: 117–47. [PubMed: 31537104]
4. NCJDRSU. Annual report. 2017.
5. Maddox RA, Person MK, Blevins JE, et al. Prion disease incidence in the United States: 2003–2015. *Neurology* 2020; 94(2): e153–e7. [PubMed: 31757870]
6. Webb TE, Pal S, Siddique D, et al. First Report of Creutzfeldt-Jakob Disease Occurring in 2 Siblings unexplained by PRNP mutation. *J Neuropathol Exp Neurol* 2008; 67(9): 838–41. [PubMed: 18716560]
7. Mead S, Uphill J, Beck J, et al. Genome-wide association study in multiple human prion diseases suggests genetic risk factors additional to PRNP. *Hum Mol Genet* 2011; 21(8): 1897–906. [PubMed: 22210626]
8. Sanchez-Juan P, Bishop MT, Kovacs GG, et al. A genome wide association study links glutamate receptor pathway to sporadic Creutzfeldt-Jakob disease risk. *PLoS One* 2014; 10(4): e0123654. [PubMed: 25918841]
9. Mead S, Poulter M, Uphill J, et al. Genetic risk factors for variant Creutzfeldt-Jakob disease: a genome-wide association study. *Lancet Neurol* 2009; 8(1): 57–66. [PubMed: 19081515]

10. Sanchez-Juan P, Bishop MT, Aulchenko YS, et al. Genome-wide study links MTMR7 gene to variant Creutzfeldt-Jakob risk. *Neurobiol Aging* 2012; 33(7): 1487 e21–8.
11. Kichaev G, Yang WY, Lindstrom S, et al. Integrating functional data to prioritize causal variants in statistical fine-mapping studies. *PLoS Genet* 2014; 10(10): e1004722. [PubMed: 25357204]
12. Hormozdiari F, Kostem E, Kang EY, Pasaniuc B, Eskin E. Identifying causal variants at loci with multiple signals of association. *Genetics* 2014; 198(2): 497–508. [PubMed: 25104515]
13. Hormozdiari F, van de Bunt M, Segre AV, et al. Colocalization of GWAS and eQTL Signals Detects Target Genes. *Am J Hum Genet* 2016; 99(6): 1245–60. [PubMed: 27866706]
14. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013; 45(6): 580–5. [PubMed: 23715323]
15. Kohn PC, Stoltze L, Flechsig E, Enari M, Weissmann C. A quantitative, highly sensitive cell-based infectivity assay for mouse scrapie prions. *Proc Natl Acad Sci U S A* 2003; 100(20): 11666–71. [PubMed: 14504404]
16. Speed D, Balding DJ. SumHer better estimates the SNP heritability of complex traits from summary statistics. *Nat Genet* 2019; 51(2): 277–84. [PubMed: 30510236]
17. Yang J, Lee SH, Goddard ME, Visscher PM. GCTA: a tool for genome-wide complex trait analysis. *Am J Hum Genet* 2011; 88(1): 76–82. [PubMed: 21167468]
18. Collinge J, Clarke AR. A general model of prion strains and their pathogenicity. *Science* 2007; 318(5852): 930–6. [PubMed: 17991853]
19. Mead S, Burnell M, Lowe J, et al. Clinical Trial Simulations Based on Genetic Stratification and the Natural History of a Functional Outcome Measure in Creutzfeldt-Jakob Disease. *JAMA Neurol* 2016; 73(4): 447–55. [PubMed: 26902324]
20. Thompson AG, Lowe J, Fox Z, et al. The Medical Research Council Prion Disease Rating Scale: a new outcome measure for prion disease therapeutic trials developed and validated using systematic observational studies. *Brain* 2013; 136(Pt 4): 1116–27. [PubMed: 23550114]
21. Mead S, Mahal SP, Beck J, et al. Sporadic--but not variant--Creutzfeldt-Jakob disease is associated with polymorphisms upstream of PRNP exon 1. *Am J Hum Genet* 2001; 69(6): 1225–35. [PubMed: 11704923]
22. Bratosiewicz-Wasik J, Smolen-Dzirba J, Rozemuller AJ, et al. Association between the PRNP 136R polymorphism and the occurrence of sporadic Creutzfeldt-Jakob disease. *Prion* 2012; 6(4): 413–6. [PubMed: 22895088]
23. Sanchez-Juan P, Bishop MT, Croes EA, et al. A polymorphism in the regulatory region of PRNP is associated with increased risk of sporadic Creutzfeldt-Jakob disease. *BMC Med Genet* 2011; 12: 73. [PubMed: 21600043]
24. Vollmert C, Windl O, Xiang W, et al. Significant association of a M129V independent polymorphism in the 5' UTR of the PRNP gene with sporadic Creutzfeldt-Jakob disease in a large German case-control study. *J Med Genet* 2006; 43(10): e53. [PubMed: 17047093]
25. Consortium GT. The Genotype-Tissue Expression (GTEx) project. *Nat Genet* 2013; 45(6): 580–5. [PubMed: 23715323]
26. Meissner B, Kallenberg K, Sanchez-Juan P, et al. MRI and clinical syndrome in dura mater-related Creutzfeldt-Jakob disease. *J Neurol* 2009; 256(3): 355–63. [PubMed: 19159063]
27. Koriath C, Kenny J, Adamson G, et al. Predictors for a dementia gene mutation based on gene-panel next-generation sequencing of a large dementia referral series. *Mol Psychiatry* 2018.
28. Rydbirk R, Folke J, Winge K, Aznar S, Pakkenberg B, Brudek T. Assessment of brain reference genes for RT-qPCR studies in neurodegenerative diseases. *Sci Rep* 2016; 6: 37116. [PubMed: 27853238]
29. Brown CA, Schmidt C, Poulter M, et al. In vitro screen of prion disease susceptibility genes using the scrapie cell assay. *Hum Mol Genet* 2014; 23(19): 5102–8. [PubMed: 24833721]
30. Goold R, Rabbani S, Sutton L, et al. Rapid cell-surface prion protein conversion revealed using a novel cell system. *Nat Commun* 2011; 2: 281. [PubMed: 21505437]
31. Claussnitzer M, Cho JH, Collins R, et al. A brief history of human disease genetics. *Nature* 2020; 577(7789): 179–89. [PubMed: 31915397]

32. Wendler F, Tooze S. Syntaxin 6: the promiscuous behaviour of a SNARE protein. *Traffic* 2001; 2(9): 606–11. [PubMed: 11555414]
33. Yamasaki T, Suzuki A, Hasebe R, Horiuchi M. Retrograde Transport by Clathrin-Coated Vesicles is Involved in Intracellular Transport of PrP(Sc) in Persistently Prion-Infected Cells. *Sci Rep* 2018; 8(1): 12241. [PubMed: 30115966]
34. Yim YI, Park BC, Yadavalli R, Zhao X, Eisenberg E, Greene LE. The multivesicular body is the major internal site of prion conversion. *J Cell Sci* 2015; 128(7): 1434–43. [PubMed: 25663703]
35. Bartoletti-Stella A, Corrado P, Mometto N, et al. Analysis of RNA Expression Profiles Identifies Dysregulated Vesicle Trafficking Pathways in Creutzfeldt-Jakob Disease. *Mol Neurobiol* 2019; 56(7): 5009–24. [PubMed: 30446946]
36. Goold R, McKinnon C, Tabrizi SJ. Prion degradation pathways: Potential for therapeutic intervention. *Mol Cell Neurosci* 2015; 66(Pt A): 12–20. [PubMed: 25584786]
37. Jones E, Mead S. Genetic risk factors for Creutzfeldt-Jakob disease. *Neurobiol Dis* 2020; 142: 104973. [PubMed: 32565065]
38. Collinge J Mammalian prions and their wider relevance in neurodegenerative diseases. *Nature* 2016; 539(7628): 217–26. [PubMed: 27830781]
39. Colin M, Dujardin S, Schraen-Maschke S, et al. From the prion-like propagation hypothesis to therapeutic strategies of anti-tau immunotherapy. *Acta Neuropathol* 2020; 139(1): 3–25. [PubMed: 31686182]
40. Chen JA, Chen Z, Won H, et al. Joint genome-wide association study of progressive supranuclear palsy identifies novel susceptibility loci and genetic correlation to neurodegenerative diseases. *Mol Neurodegener* 2018; 13(1): 41. [PubMed: 30089514]
41. Hoglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. *Nat Genet* 2011; 43(7): 699–705. [PubMed: 21685912]
42. Takahashi T, Suzuki T. Role of sulfatide in normal and pathological cells and tissues. *J Lipid Res* 2012; 53(8): 1437–50. [PubMed: 22619219]
43. Platt FM, d'Azzo A, Davidson BL, Neufeld EF, Tift CJ. Lysosomal storage diseases. *Nat Rev Dis Primers* 2018; 4(1): 27. [PubMed: 30275469]
44. Honke K, Hirahara Y, Dupree J, et al. Paranodal junction formation and spermatogenesis require sulfoglycolipids. *Proc Natl Acad Sci U S A* 2002; 99(7): 4227–32. [PubMed: 11917099]
45. Zhao B, Zhang J, Ibrahim JG, et al. Large-scale GWAS reveals genetic architecture of brain white matter microstructure and genetic overlap with cognitive and mental health traits (n = 17,706). *Mol Psychiatry* 2019.
46. Klein TR, Kirsch D, Kaufmann R, Riesner D. Prion rods contain small amounts of two host sphingolipids and revealed by thin-layer chromatography and mass spectrometry. *Biol Chem* 1998; 379(655): 666.
47. Agostini F, Dotti CG, Perez-Canamas A, Ledesma MD, Benetti F, Legname G. Prion protein accumulation in lipid rafts of mouse aging brain. *PLoS One* 2013; 8(9): e74244. [PubMed: 24040215]
48. Hwang D, Lee IY, Yoo H, et al. A systems approach to prion disease. *Mol Syst Biol* 2009; 5: 252. [PubMed: 19308092]
49. Bremer J, Baumann F, Tiberi C, et al. Axonal prion protein is required for peripheral myelin maintenance. *Nat Neurosci* 2010; 13(3): 310–8. [PubMed: 20098419]
50. Kuffer A, Lakkaraju AK, Mogha A, et al. The prion protein is an agonistic ligand of the G protein-coupled receptor Adgrg6. *Nature* 2016; 536(7617): 464–8. [PubMed: 27501152]
51. Skedsmo FS, Malachin G, Vage DI, et al. Demyelinating polyneuropathy in goats lacking prion protein. *FASEB J* 2020; 34(2): 2359–75. [PubMed: 31907995]

Research in context

Evidence before this study

The rarity of the disease has been limiting in previous genome-wide association studies (GWAS) for sporadic Creutzfeldt-Jakob disease (sCJD) risk. A PubMed search with the terms (prion OR “creutzfeldt”) AND (“genome wide association” OR GWAS) (without language restrictions) identified four relevant GWAS publications including two directly investigating sCJD risk through genome-wide analyses, however sample sizes were not sufficient to identify statistically significant associations outside of the known risk at *PRNP*. Further studies into genetic risk factors for sCJD have primarily utilised targeted replication of putative risk variants or candidate gene studies to propose association.

Added value of this study

Through international collaboration of sample resources, this study is the first GWAS to identify genetic variants associated with sCJD risk outside of *PRNP* at genome-wide significance. Two of these variants (within *STX6* and *GAL3ST1*) were statistically robust to replication in an independent cohort, totalling 5208 sCJD patients in the two-stage study design. Through statistical fine-mapping and analysis of exome sequencing and gene expression data we propose likely causal genes and mechanisms for both novel associations. We use patient brain samples and cell-based assays to further investigate the biological implications of these in relevant systems. Two further loci at *PDIA4* and *BMERB1* were also associated with sCJD risk in gene-wide tests.

Implications of all the available evidence

Identification of two novel non-*PRNP* loci conferring sCJD risk will provide further avenues for research with increased evidence to support a role of modified intracellular trafficking and sphingolipid metabolism within sCJD biology, with the potential to inform new therapeutic approaches. With the shared genetic risk of variants within *STX6* and those previously identified for tauopathy progressive supranuclear palsy, this study also provides support to the notion of a common “prion-like” mechanism for related neurodegenerative disorders and thus potential for shared treatments. The generation of publicly available summary statistics can be used for further investigations by researchers.

Figure 1. Manhattan plot for significant variants.

The nearest gene to each genome-wide significant locus (indicated by the red horizontal line) is labelled as well as genes significant in gene-wide tests.

Figure 2. Statistical fine-mapping using CAVIAR.

CAVIAR utilizes summary statistics and LD structure to predict the probability of each variant being causal, producing a ‘causal set’ with 95% probability of containing the causal SNP, whilst allowing for the possibility of multiple causal SNPs. Each locus was defined as 100 variants upstream and downstream of the top SNP. Plots show causal posterior probability of each variant at (a) *PRNP*, (b) *STX6* and (c) *GAL3ST1* coloured by LD (1000G; EUR) with the top SNP. Circles indicate variants within the 95% causal set.

Figure 3. Co-localisation of GWAS results at *STX6* locus with eQTLs for *STX6* expression in the caudate, putamen and hypothalamus and *KIAA1614* expression in the tibial artery.

Plot of $-\log_{10}$ of P-values from the GWAS association analysis at the *STX6* locus (black) and the eQTL association analysis from the GTEx dataset (v7) (red) for: (a) *STX6* expression in the caudate, (b) *STX6* expression in the putamen, (c) *STX6* expression in the hypothalamus, (d) *KIAA1614* expression in the tibial artery. Peaks correspond to the CLPP in the eCAVIAR analysis with a higher degree of colocalisation with increasing CLPP (see appendix p 12).

Figure 4: Scrapie cell assay (SCA) to measure prion propagation in N2aPK1/2 cells with modified *Stx6* expression.

N2aPK1/2 cells were transfected with pRetroSuper vectors containing *Stx6* ('shSTX6 1', 'shSTX6 2') or *Prnp* ('shPRNP') targeting shRNAs or a scrambled non-silencing ('shScramble 1', 'shScramble 2') shRNA sequence for controls. Samples were taken prior to SCA for immunoblot (n=3) and expression normalised to untransfected N2aPK1/2 (indicated by dashed line). **(a–b)** Knockdown of syntaxin-6 protein determined by **(a)** immunoblot with anti-syntaxin-6 antibody with **(b)** band intensity measured relative to β-actin loading control (Student's t-test). **(c–d)** Knockdown of PrP^C determined by **(c)** immunoblot with anti-PrP antibody ICSM18 with **(d)** band intensity measured relative to β-actin loading control (Student's t-test). **(e)** Average spot count of infected cell number post-4th split in SCA following infection with RML at 3×10^{-6} dilution (one-way ANOVA

with Tukey's post-hoc test on log-transformed data). Statistical associations of knockdown lines relative to controls indicated; other results omitted for clarity. All error bars show mean $\pm$ SEM; *P<0.05, ** P<0.01, *** P<0.001.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.
Main results of discovery and replication stages.

PRNP, *STX6* and *GAL3ST1* SNPs were successfully replicated in an independent cohort ($P < 0.05$) with a similar effect as the discovery phase.

		rs1799990	rs3747957	rs2267161	rs9065	rs6498552
	Nearest gene	<i>PRNP</i>	<i>STX6</i>	<i>GAL3ST1</i>	<i>PDIA4</i>	<i>BMERB1</i>
	Location (GRCh37)	20:4680251	1:180953853	22:30953295	7:148700849	16:15539901
	Type of mutation	Missense Exonic	Synonymous Exonic	Missense Exonic	3' UTR Exonic	Intronic
	Risk allele	A	A	C	T	T
	Minor allele	G	A	T	T	T
Discovery stage	No. cases	4110	4110	4110	4110	4110
	No. controls	13569	13569	13569	13569	13569
	MAF cases	0.288	0.452	0.289	0.220	0.120
	MAF controls	0.340	0.410	0.322	0.191	0.102
	<i>P</i> -value	2.68×10^{-15}	9.74×10^{-9}	8.60×10^{-10}	1.66×10^{-6}	5.75×10^{-8}
	Odds ratio (95 CI)	1.23 (1.17–1.30)	1.16 (1.10–1.22)	1.18 (1.12–1.25)	1.17 (1.09–1.24)	1.27 (1.16–1.38)
Replication stage	No. cases	1,098	1,098	1,098	1,098	1,098
	No. controls	498,016	498,016	498,016	498,016	498,016
	MAF cases	0.294	0.450	0.302	0.203	0.105
	MAF controls	0.328	0.420	0.326	0.204	0.0972
	<i>P</i> -value; replication cohorts	0.0049	0.0034	0.042	0.88	0.17
	Odds ratio	1.15	1.14	1.11	1.01	1.11
	<i>P</i> -value; replication plus discovery meta-analysis	9.61×10^{-17}	1.23×10^{-10}	1.97×10^{-10}	8.49×10^{-5}	6.45×10^{-8}

¹ Replication minor allele frequencies (MAF) were estimated as a weighted mean of each cohort based on case sample number. Odds ratio shown relative to the risk allele.